Medical treatment institutions in Shanghai have been ordered to suspend use of a human immunoglobulin for intravenous injection by the city's health authorities on Wednesday.
China Meheco Xinxing Pharma Co Ltd, a pharmaceutical company in Shanghai, has been ordered to suspend operation and launch an emergency recall of the immunoglobulin by the city's drug watchdog.
The manufacturing and testing records of the company have been seized with investigation underway and samples of relevant immunoglobulin have been sent for testing, according to the city's drug authorities.
Law enforcement officials and experts organized by the watchdog are at the scene to conduct an investigation.
China's drug watchdog has also dispatched a team of experts to Shanghai to conduct an on-the-spot investigation.
The city government has ordered scrutiny and sealing of relevant drug products immediately and enhanced management to ensure the safe use of medicine products of the public based on the notice from the National Medical Products Administration and National Health Commission of China.